clinical trial · NCT06435039
A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers
Syneos Health·phase1·terminated·n = 12
Healthy VolunteersAPL-1202APL-1501
brief summary
The primary objective of the study is to assess safety and tolerability following administration of single doses of APL-1202 (immediate release) IR tablets and APL-1501 extended release (ER) capsules in healthy participants.
started
Jun 21, 2024
primary completion
Jul 16, 2024
completion
Jul 16, 2024
last updated
Jan 31, 2025
official title
A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of APL-1501 ER Capsules Compared to APL-1202 IR Tablets in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol